Bliemsrieder E, Kaissis G, Grashei M, Topping G, Altomonte J, Hundshammer C, Lohöfer F, Heid I, Keim D, Gebrekidan S, Trajkovic-Arsic M, Winkelkotte A, Steiger K, Nawroth R, Siveke J, Schwaiger M, Makowski M, Schilling F, Braren R. Hyperpolarized 13C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC. Sci Rep. 2021 Jan 13;11(1):1191. doi: 10.1038/s41598-020-80952-4. PMID: 33441943

Lunger L, Retz M, Bandur M, Souchay M, Vitzthum E, Jäger M, Weirich G, Schuster T, Autenrieth M, Kübler H, Maurer T, Thalgott M, Herkommer K, Koll F, Gschwend JE, Nawroth R, Heck MM. KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy. Prostate Cancer Prostatic Dis. 2020 Sep 25. doi: 10.1038/s41391-020-00283-3. Online ahead of print. PMID: 32978525

Schulz WA, Hoffmann MJ, Niegisch G, Füssel S, Nawroth R. Report from the 9th symposium of the German Association for Bladder Cancer Research. Urologe A. 2020 Jun;59(6):731-732. doi: 10.1007/s00120-020-01181-1. PMID: 32242269

Heck MM, Koll FJ, Retz M, Autenrieth M, Magg K, Lunger L, Gschwend JE, Nawroth R.  Molecular lymph node staging for bladder cancer patients undergoing radical cystectomy with pelvic lymph node dissection. Urol Oncol. 2020 Jul;38(7):639.e11-639.e19. doi: 10.1016/j.urolonc.2020.01.018. Epub 2020 Mar 4. PMID: 32146127

Hindupur SV, Schmid SC, Koch JA, Youssef A, Baur EM, Wang D, Horn T, Slotta-Huspenina J, Gschwend JE, Holm PS, Nawroth R. STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy. Int J Mol Sci. 2020 Feb 7;21(3):1106. doi: 10.3390/ijms21031106. PMID: 32046095

Williams SB, Black PC, Dyrskjøt L, Seiler R, Schmitz-Dräger B, Nawroth R, Todenhöfer T, Kamat AM, Goebell PJ. Re: Aurélie Kamoun, Aurélien de Reyniès, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol 2020;77:420-33: A Statement from the International Bladder Cancer Network. Eur Urol. 2020 Apr;77(4):e105-e106. doi: 10.1016/j.eururo.2019.11.011. Epub 2019 Nov 29. PMID: 31787429

Seiler R, Black PC, Williams SB, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ. Editorial: Bladder cancer within the focus of basic and clinical research. Sixth IBCN Seminars Series. Urol Oncol. 2019 Nov;37(11):815-817. doi: 10.1016/j.urolonc.2019.06.025. Epub 2019 Jul 31. PMID: 31377169

Tong Z, Sathe A, Ebner B, Qi P, Veltkamp C, Gschwend JE, Holm PS, Nawroth R. Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer. J Exp Clin Cancer Res. 2019 Jul 22;38(1):322. doi: 10.1186/s13046-019-1322-9. PMID: 31331377

Lichtenegger E, Koll F, Haas H, Mantwill K, Janssen KP, Laschinger M, Gschwend J, Steiger K, Black PC, Moskalev I, Nawroth R, Holm PS. The Oncolytic Adenovirus XVir-N-31 as a Novel Therapy in Muscle-Invasive Bladder Cancer. Hum Gene Ther. 2019 Jan;30(1):44-56. doi: 10.1089/hum.2018.026. Epub 2018 Aug 3. PMID: 29916265

Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ. New Horizons in Bladder Cancer Research: Report of the 15th Meeting of the International Bladder Cancer Network (IBCN) in Lisbon, Portugal, October 21-23, 2017. Bladder Cancer. 2018 Jul 30;4(3):339-342. doi: 10.3233/BLC-189032. PMID: 3011244

Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ. Editorial: Managing locally advanced bladder cancer. Third International Bladder Cancer Network seminars series. Urol Oncol. 2018 Sep;36(9):403-404. doi: 10.1016/j.urolonc.2017.11.006. Epub 2018 Mar 13. PMID: 29548621

Heck MM, Retz M, Bandur M, Souchay M, Vitzthum E, Weirich G, Schuster T, Autenrieth M, Kübler H, Maurer T, Thalgott M, Herkommer K, Gschwend JE, Nawroth R. Molecular Lymph Node Status for Prognostic Stratification of Prostate Cancer Patients Undergoing Radical Prostatectomy with Extended Pelvic Lymph Node Dissection. Clin Cancer Res. 2018 May 15;24(10):2342-2349. doi: 10.1158/1078-0432.CCR-17-3771. Epub 2018 Feb 20. PMID: 29463560

Sathe A, Chalaud G, Oppolzer I, Wong KY, von Busch M, Schmid SC, Tong Z, Retz M, Gschwend JE, Schulz WA, Nawroth R. Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy. PLoS One. 2018 Jan 22;13(1):e0190854. doi: 10.1371/journal.pone.0190854. eCollection 2018. PMID: 29357370

Seitz AK, Thoene S, Bietenbeck A, Nawroth R, Tauber R, Thalgott M, Schmid S, Secci R, Retz M, Gschwend JE, Ruland J, Winter C, Heck MM. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide. Eur Urol. 2017 Nov;72(5):828-834. doi: 10.1016/j.eururo.2017.07.024. Epub 2017 Aug 14. PMID: 28818355

Hohl A, Ramms AS, Dohmen C, Mantwill K, Bielmeier A, Kolk A, Ruppert A, Nawroth R, Holm PS. Adenovirus Particle Quantification in Cell Lysates Using Light Scattering. Hum Gene Ther Methods. 2017 Oct;28(5):268-276. doi: 10.1089/hgtb.2017.052. Epub 2017 Aug 14. PMID: 28806885

Jefferies B, Lenze F, Sathe A, Truong N, Anton M, von Eisenhart-Rothe R, Nawroth R, Mayer-Kuckuk P. Non-invasive imaging of engineered human tumors in the living chicken embryo. Sci Rep. 2017 Jul 10;7(1):4991. doi: 10.1038/s41598-017-04572-1. PMID: 28694510

Dyrskjøt L, Reinert T, Algaba F, Christensen E, Nieboer D, Hermann GG, Mogensen K, Beukers W, Marquez M, Segersten U, Høyer S, Ulhøi BP, Hartmann A, Stöhr R, Wach S, Nawroth R, Schwamborn K, Tulic C, Simic T, Junker K, Harving N, Petersen AC, Jensen JB, Keck B, Grimm MO, Horstmann M, Maurer T, Steyerberg EW, Zwarthoff EC, Real FX, Malats N, Malmström PU, Ørntoft TF. Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study. Eur Urol. 2017 Sep;72(3):461-469. doi: 10.1016/j.eururo.2017.05.040. Epub 2017 Jun 2. PMID: 28583312

Skowron MA, Sathe A, Romano A, Hoffmann MJ, Schulz WA, van Koeveringe GA, Albers P, Nawroth R, Niegisch G. Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma. Urol Oncol. 2017 Sep;35(9):544.e11-544.e23. doi: 10.1016/j.urolonc.2017.05.003. Epub 2017 May 25. PMID: 28551413

Schmid SC, Sathe A, Guerth F, Seitz AK, Heck MM, Maurer T, Schwarzenböck SM, Krause BJ, Schulz WA, Stoehr R, Gschwend JE, Retz M; German Bladder Cancer Network, Nawroth R. Wntless promotes bladder cancer growth and acts synergistically as a molecular target in combination with cisplatin. Urol Oncol. 2017 Sep;35(9):544.e1-544.e10. doi: 10.1016/j.urolonc.2017.04.015. Epub 2017 May 10. PMID: 28501564

Seitz AK, Christensen LL, Christensen E, Faarkrog K, Ostenfeld MS, Hedegaard J, Nordentoft I, Nielsen MM, Palmfeldt J, Thomson M, Jensen MT, Nawroth R, Maurer T, Ørntoft TF, Jensen JB, Damgaard CK, Dyrskjøt L. Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer. Sci Rep. 2017 Mar 24;7(1):395. doi: 10.1038/s41598-017-00327-0. PMID: 28341852

Vlahou A, Black PC, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ. Taking the next step-Advancing bladder cancer management. Urol Oncol. 2016 Oct;34(10):435-6. doi: 10.1016/j.urolonc.2016.03.004. PMID: 27658683

 Schwarzenböck SM, Eiber M, Kundt G, Retz M, Sakretz M, Kurth J, Treiber U, Nawroth R, Rummeny EJ, Gschwend JE, Schwaiger M, Thalgott M, Krause BJ. Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer. Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2105-2113. doi: 10.1007/s00259-016-3439-9. Epub 2016 Jun 17. PMID: 27317482

Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MBH, Nielsen MM, Marquez M, Segersten U, Aine M, Höglund M, Birkenkamp-Demtröder K, Fristrup N, Borre M, Hartmann A, Stöhr R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KEM, Jensen JB, Pedersen JS, Malmström PU, Malats N, Real FX, Zwarthoff EC, Ørntoft TF, Dyrskjøt L. Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. Cancer Cell. 2016 Jul 11;30(1):27-42. doi: 10.1016/j.ccell.2016.05.004. Epub 2016 Jun 16. PMID: 27321955

Heck MM, Thalgott M, Schmid SC, Oh WK, Gong Y, Wang L, Zhu J, Seitz AK, Porst D, Höppner M, Retz M, Gschwend JE, Nawroth R. A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer. Prostate. 2016 Sep;76(13):1160-8. doi: 10.1002/pros.23202. Epub 2016 May 16. PMID: 27198487

Füssel S, Kramer MW, Stöhr R, Olbert P, Nawroth R, Schulz WA. Report on the 5th symposium of the German research network bladder carcinoma. Urologe A. 2016 May;55(5):663-4. doi: 10.1007/s00120-016-0100-y. PMID: 27138635

Wang L, Gong Y, Chippada-Venkata U, Heck MM, Retz M, Nawroth R, Galsky M, Tsao CK, Schadt E, de Bono J, Olmos D, Zhu J, Oh WK. A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. BMC Med. 2015 Aug 21;13:201. doi: 10.1186/s12916-015-0442-0. PMID: 26297150

Matthias M. Heck, Markus A. Thaler, Sebastian C. Schmid, Anna-Katharina Seitz, Robert Tauber, Hubert Kübler, Tobias Maurer, Mark Thalgott, Georgios Hatzichristodoulou, Michael Höppner, Roman Nawroth, Peter B. Luppa, Jürgen E. Gschwend, Margitta Retz. Chromogranin A and neuron-specific enolase serum levels as predictors of treatment outcome in metastatic castration-resistant prostate cancer patients under abiraterone therapy. BJU Int. 2016 Mar 31. doi: 10.1111/bju.13493. 2017 Jan;119(1):30-37. doi: 10.1111/bju.13493. Epub 2016 Apr 27.

Horn T, Laus J, Seitz AK, Maurer T, Schmid SC, Wolf P, Haller B, Winkler M, Retz M, Nawroth R, Gschwend JE, Kübler HR, Slotta-Huspenina The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. World J Urol. 2016 Feb;34(2):181-7. doi: 10.1007/s00345-015-1615-3. Epub 2015 Jun 9.

Anuja Sathe, Nicole Koshy, Sebastian C. Schmid, Mark Thalgott, Sarah M. Schwarzenböck, Bernd J. Krause2, Per S. Holm1, Juergen E. Gschwend 1, Margitta Retz 1, RomanNawroth 1 CDK4/6-inhibition controls proliferation of bladder cancer and transcription of RB1, J Urol. 2016 Mar;195(3):771-9. doi: 10.1016/j.juro.2015.08.082. Epub 2015 Aug 28.

Mark Thalgott, Brigitte Rack, Thomas Horn, Matthias M. Heck, Matthias Eiber, Hubert Kübler, Margitta Retz, Jürgen E. Gschwend, Ulrich Andergassen and Roman Nawroth. Detection of Circulating Tumour Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy Anticancer Res. 2015 Oct;35(10):5679-85.

Schwarzenböck SM, Gertz J, Souvatzoglou M, Kurth J, Sachs D, Nawroth R, Treiber U, Schuster T, Senekowitsch-Schmidtke R, Schwaiger M, Ziegler SI, Henriksen G, Wester HJ, Krause BJ. Comparison of [11C]Choline ([11C]CHO) and S(+)-β-Methyl-[11C]Choline ([11C]SMC) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model. Mol Imaging Biol. 2016 Jun;18(3):393-401. doi: 10.1007/s11307-015-0901-1. PMID: 26483088

Thalgott M, Rack B, Eiber M, Souvatzoglou M, Heck MM, Kronester C, Andergassen U, Kehl V, Krause BJ, Gschwend JE, Retz M, Nawroth R. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients. BMC Cancer. 2015 Jun 9;15:458. doi: 10.1186/s12885-015-1478-4.

Thalgott M, Heck MM, Eiber M, Souvatzoglou M, Hatzichristodoulou G, Kehl V, Krause BJ, Rack B, Retz M, Gschwend JE, Andergassen U, Nawroth R. Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy. J Cancer Res Clin Oncol. 2015 Feb 24. [Epub ahead of print] PMID:25708944

Boormans JL, Zwarthoff EC, Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ. New horizons in bladder cancer research. Urol Oncol. 2020 Dec;38(12):867-885. doi: 10.1016/j.urolonc.2018.12.014. Epub 2019 Mar 7.

Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ. Editorial: Basic research in bladder cancer - refining the tools. 3rd IBCN seminars series1. Urol Oncol. 2020 Dec;38(12):855-857. doi: 10.1016/j.urolonc.2019.01.003. Epub 2019 Jan 23.

Williams SB, Hudgins HK, Ray-Zack MD, Chamie K, Smaldone MC, Boorjian SA, Daneshmand S, Black PC, Kamat AM, Goebell PJ, Seiler R, Schmitz-Drager B, Nawroth R, Baillargeon J, Klaassen Z, Kulkarni GS, Kim SP, Lee EK, Holzbeierlein JM, Hollenbeck BK, Gore JL. Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. Eur Urol Oncol. 2019 Mar;2(2):119-125. doi: 10.1016/j.euo.2018.07.006. Epub 2018 Aug 14.

Sathe A, Nawroth R. Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer. Methods Mol Biol. 2018;1655:335-350. doi: 10.1007/978-1-4939-7234-0_23.

Pan Q, Sathe A, Black PC, Goebell PJ, Kamat AM, Schmitz-Draeger B, Nawroth R. CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer. Bladder Cancer. 2017 Apr 27;3(2):79-88. doi: 10.3233/BLC-170105.

Hofbauer S, Kalogirou C, Roghmann F, Seitz AK, Vallo S, Wezel F, Worst T, Nawroth R. Modern networks : Topics in the working group "Bladder cancer research" of the GeSRU Academics Urologe A. 2017 Feb;56(2):202-207. doi: 10.1007/s00120-016-0217-z.

Holm PS, Retz M, Gschwend JE, Nawroth R. YB-1-based virotherapy : A new therapeutic intervention for transitional cell carcinoma of the bladder? Urologe A. 2016 Mar;55(3):356-63. doi: 10.1007/s00120-015-3811-6.

Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I, Sharma D, Saxena NK, Singh N, Vlachostergios PJ, Guo S, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Nowsheen S. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol. 2015 Dec;35 Suppl(Suppl):S25-S54. doi: 10.1016/j.semcancer.2015.02.006. Epub 2015 Apr 17.

Nawroth R, Goebell PJ, Kamat AM, Kiemeney LA, Schmitz-Dräger BJ. Current concepts--future needs: the 10th Annual Meeting of the International Bladder Cancer Network (IBCN) in Nijmegen, The Netherlands, September 20th to 22nd, 2012. Urol Oncol. 2014 Oct;32(7):1049-50. doi: 10.1016/j.urolonc.2014.02.008. Epub 2014 Oct 29.

Nawroth, R., Weckermann, D., Retz, M., Prostate and bladder cancer: detection of disseminated tumor cells in bone marrow. Urologe 2014 Apr;53(4):514-8. doi: 10.1007/s00120-014-3445-0.

Heck, MM., Retz M., Nawroth, R., Molecular lymph node staging in prostate and bladder cancer. Urologe 2014 Apr;53(4):484-90. doi: 10.1007/s00120-014-3441-4

Keck B, Merseburger AS, Stöhr R, Füssel S, Hoffmann MJ, Schmid S, Olbert P, Hartmann A, Nawroth R., Bladder cancer in focus. Update 2012 of the German Bladder Cancer Association. Urologe 2013, DOI 10.1007/s00120-012-3111-3

Autenrieth M, Gschwend JE, Nawroth R, Retz M. The significance of extended pelvic lymphadenectomy for muscle invasive bladder cancer. Der Onkologe November 2012, Volume 18, Issue 11, pp 985-993